Products for Research Use Only

TG 100572

CAT: 0804-HY-10184Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10184Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
CAS Number
867334-05-2
UNSPSC
12352005
Target
FGFR; PDGFR; Src; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/TG-100572.html
Solubility
DMSO : ≥ 150 mg/mL
Smiles
ClC1=CC=C(O)C=C1C2=CC(C)=C(N=C(NC(C=C3)=CC=C3OCCN4CCCC4)N=N5)C5=C2
Molecular Formula
C26H26ClN5O2
Molecular Weight
475.97
References & Citations
[1]Doukas J, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216 (1) :29-37.|[2]Palanki MS, et al. Development of prodrug 4-chloro-3- (5-methyl-3-{[4- (2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl) phenyl benzoate (TG100801) : a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51 (6) :1546-59.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1
Citation 01
ACS Appl Mater Interfaces. 2025 Aug 6;17 (31) :44160-44177.|Am J Pathol. 2019 Oct;189 (10) :2090-2101.|Science. 2017 Dec 1;358 (6367) :eaan4368.